Unilever licenses Japanese peptide for blood pressure control range

Related tags Blood pressure Milk Hypertension

Unilever will launch Europe's second blood pressure-controlling
dairy beverage in Portugal next month, writes Dominique

The product will be the first of a range of blood pressure-controlling foods to be developed by the firm for the European market using the AmealPeptide ingredient licensed from Japan's Calpis​.

Finnish company Valio​ is to date the only European company to market a functional food - its Evolus fermented milk, which carries a claim that it can help reduce blood pressure.

This product, first available in Finland in 2000, was recently extend to the Spanish and Portugese markets. Yet this category remains a rich, untapped opportunity, with an estimated 100 million Europeans suffering from high blood pressure.

About two thirds of strokes and half the incidence of heart disease are attributable to raised blood pressure, according to the World Health Organisation. Globally, high blood pressure is estimated to cause 7.1 million deaths, about 13 per cent of the total and about 4.4 per cent of the total chronic disease burden, and this is set to increase.

More than 1.5 billion people will have high blood pressure by 2025, or around one in three adults over the age 20, US experts warned​ earlier this year. They forecast a 60 per cent increase in adults with high blood pressure over the next 20 years, with the world's poorest countries set to be worst hit.

Calpis launched the AmealPeptide, also known as lactotripeptide, in 1997 in the form of Ameal S, which has FOSHU (Food for Specified Health Use) status on the Japanese market. It accounts for about 70 per cent of the sales of blood pressure category FOSHU products.

Unilever​ will add it to a new milk drink under the Becel brand, joining Unilever's cholesterol-lowering margarine and dairy products also targeted at heart health.

A spokesman for the firm said it was not ready to disclose how the product will be marketed and whether it will carry a health claim.

AmealPeptide has been produced under contract in Denmark since May, not only for the European market but also to supply Japan and future US sales.

Like the Evolus ingredient, it is produced by the enzymatic hydrolysis of casein (milk protein) that creates tripeptides, shown in trials to reduce blood pressure.

Dutch ingredients group DMV International also makes a milk peptide for blood pressure-lowering (C12 peptide) while Chr Hansen, the food industry's biggest supplier of probiotics, recently announced that it had developed a bacteria named Cardi-04, shown in animal trials to lower blood pressure.

Calpis said on Thursday that it wants its functional ingredients business to become one of its mainstay activities and that it would seek to aggressively expand sales in the United States and other areas.

Related news

Show more

Related products

show more

Krill oil supports six key areas of healthy aging

Krill oil supports six key areas of healthy aging

Content provided by Aker BioMarine | 14-Feb-2024 | White Paper

The global population is getting older—according to WHO by 2050 the world’s population over 60 years will double and the population above 80 years will...

Latest Research Findings on Omega-3s for Heart Health

Latest Research Findings on Omega-3s for Heart Health

Content provided by GC Rieber VivoMega™ | 12-Feb-2024 | White Paper

According to Grandview Research, the global omega-3 market is a $2.62 billion market and is one of the fastest-growing segments in the dietary supplement...

Dynamic Duo - More Power, Less Fatigue

Dynamic Duo - More Power, Less Fatigue

Content provided by Enovate Biolife LLC | 23-Jan-2024 | White Paper

Better physical performance & vitality have deep connections to muscular as well as cardio-respiratory health.

Related suppliers

Follow us


View more